Insulin glargine (LANTUS®) is a long-acting basal insulin analog. The aim of this observational study was to investigate the effect of adding insulin glargine ...
INSULIN GLARGINE IN TYPE 2 DIABETES: AN OBSERVATIONAL STUDY OF EVERYDAY PRACTICE STEPHAN A SCHREIBER1, KERSTIN SCHNEIDER2, MATTHIAS AXEL SCHWEITZER2
614
QUICKBORN, GERMANY; 2BAD SODEN AM TAUNUS, GERMANY
1
ABSTRACT
STUDY OBJECTIVE
Statistical analysis
Body mass index
Insulin glargine (LANTUS®) is a long-acting basal insulin analog. The aim of this observational study was to investigate the effect of adding insulin glargine basal therapy to support oral antidiabetic treatment in patients with type 2 diabetes in everyday practice. In this 9-month, uncontrolled observational study, 12,216 patients with type 2 diabetes not adequately controlled on oral antidiabetic drugs (OADs) received add-on insulin glargine treatment. Dosing decisions, including any changes to OADs, were made at the physician’s discretion, reflecting everyday practice. Efficacy outcomes included baseline, 3-month and 9-month changes in A1c, fasting blood glucose (FBG), body weight and body mass index (BMI). At baseline, the mean (± SD) age of patients was 64 (± 11.3) years. Duration of diabetes was >5 years in 47% of patients, 1–5 years in 39% of patients and
